Loading...
Loading...
BFRI| Name | Value |
|---|---|
| Revenues | 7,901.0K |
| Cost of Revenue | 3,946.0K |
| Gross Profit | 3,955.0K |
| Operating Expense | 9,433.0K |
| Operating I/L | -5,467.0K |
| Other Income/Expense | -4,969.0K |
| Interest Income | 14.0K |
| Pretax | -10,436.0K |
| Income Tax Expense | 1.0K |
| Net Income/Loss | -10,437.0K |
Biofrontera Inc. is a biopharmaceutical company specializing in the commercialization of pharmaceutical products for dermatological conditions in the United States. Its flagship product, Ameluz, is a prescription drug used in combination with the RhodoLED lamp series for photodynamic therapy to treat actinic keratosis. Additionally, the company offers Xepi, a prescription cream for impetigo treatment. Biofrontera generates revenue through the sale of these prescription drugs and medical devices, catering to the needs of patients with dermatological conditions.
